Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects
Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects
This is Open-label, Randomized, 3-sequence study to compare of pharmacokinetics and
 safety/tolerability profiles betweens DA-5206, a SR formulation of bepotastine besilate and
 Talion®, a IR formulation of bepotastine besilate under fasting and fed states in healthy
 male subjects
Inclusion Criteria:

 -  Healthy male volunteer 19 years to 45 years

 -  Body mass index in the range of 18 to 29 kg/m2 and body weight greater than 50 kg

 -  The subjects personally signed and dated informed consent document after informed of
 all pertinent aspects of the study, fully understanding and determided spontaneously
 to participate

 Exclusion Criteria:

 -  Subject with serious active cardiovascular, respiratory, hepatologic, renal,
 hematologic, endocrine, urologic, immunologic, dermal, neurologic, or psychological
 disease or history of such disease

 -  Subject with acute disease within 28 days before the first dose of Investigational
 product

 -  Subject with known for history of disease which affect on the absorption,
 distribution, metabolism, excretion of drug

 -  Subjects who are unwilling or unable to use highly effective methods of contraception
 as outlined in this protocol for the duration of the study